Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.87+0.75 (+5.31%)
At close: 04:00PM EST
14.70 -0.17 (-1.14%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close14.12
Open14.11
Bid14.60 x 900
Ask14.70 x 1000
Day's range13.90 - 14.88
52-week range8.86 - 18.48
Volume2,259,614
Avg. volume3,848,859
Market cap2.676B
Beta (5Y monthly)2.48
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Yahoo Finance Video

    AMC, GME among meme stocks tanking amid market carnage

    Yahoo Finance's Ines Ferre details the losses seen in the meme stock market as sector staples continue to slide.

  • Motley Fool

    Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week

    Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were skyrocketing 40.2% higher this week as of the market close on Thursday, according to on data from S&P Global Market Intelligence. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. In addition, BioCryst stated that it has begun enrolling patients in two pivotal clinical studies evaluating its experimental oral Factor D inhibitor, BCX990, in treating rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH).

  • Zacks

    BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales

    BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.